Liting You

Dr. Liting You


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2023 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
XZXiao Zeng
Xiao Zeng
QMQiong Ma
Qiong Ma
XLXue-Ke Li
Xue-Ke Li
LYLiting You
Liting You
JLJia Li
Jia Li
YRYi-Feng Ren
Yi-Feng Ren
Lung cancer is one of the most common malignant tumors worldwide, with high morbidity and mortality due to significant individual characteristics and genetic heterogeneity. Personalized treatment is necessary to improve the overall survival rate of the patients. In recent years, the development of patient-derived organoids (PDOs) enables lung cancer diseases to be simulated in the real world, and closely reflects the pathophysiological characteristics of natural tumor occurrence and metastasis, highlighting their great potential in biomedical applications, translational medicine, and personalized treatment. However, the inherent defects of traditional organoids, such as poor stability, the tumor microenvironment with simple components and low throughput, limit their further clinical transformation and applications. In this review, we summarized the developments and applications of lung cancer PDOs and discussed the limitations of traditional PDOs in clinical transformation. Herein, we looked into the future and proposed that organoids-on-a-chip based on microfluidic technology are advantageous for personalized drug screening. In addition, combined with recent advances in lung cancer research, we explored the translational value and future development direction of organoids-on-a-chip in the precision treatment of lung cancer.

1 December 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
YZYue Zheng
Yue Zheng
BFBaijie Feng
Baijie Feng
JCJingyao Chen
Jingyao Chen
LYLiting You
Liting You
Background: Neoadjuvant immunochemotherapy may benefit patients with non-small cell lung cancer (NSCLC), but its impact requires further investigation.Methods: A meta-analysis was conducted. PubMed, Embase, Web of Science, and the Cochrane Library were searched. The study was registered in PROSPERO (registration no. CRD42022360893).Results: 60 studies of 3,632 patients were included. Comparing with neoadjuvant chemotherapy, neoadjuvant immunochemotherapy showed higher pCR (RR: 4.71, 95% CI: 3.69, 6.02), MPR (RR, 3.20, 95% CI: 2.75, 3.74), and ORR (RR, 1.46, 95% CI: 1.21, 1.77), fewer surgical complications (RR: 0.67, 95%CI: 0.48, 0.94), higher R0 resection rate (RR: 1.06, 95%CI: 1.03, 1.10, I2 = 52%), and longer 1-year and 2-year OS, without affecting TRAEs. For neoadjuvant immunochemotherapy in NSCLC, the pooled pCR rate was 0.35 (95% CI: 0.31, 0.39), MPR was 0.59 (95% CI: 0.54, 0.63), and ORR was 0.71 (95% CI: 0.66, 0.76). The pooled incidence of all grade TRAEs was 0.70 (95% CI: 0.60, 0.81), and that of >= grade 3 TRAEs was 0.24 (95% CI: 0.16, 0.32). The surgical complications rate was 0.13 (95% CI: 0.07, 0.18) and R0 resection rate was 0.98 (95% CI: 0.96, 0.99). The pooled 1-year OS was 0.97 (95%CI: 0.96, 0.99), and 2-year OS was 0.89 (95%CI: 0.83, 0.94). Patients with squamous cell carcinoma, stage III or higher PD-L1 performed better. Notably, no significant differences were observed in pCR, MPR, and ORR between 2 or more treatment cycles. Pembrolizumab-, or toripalimab-based neoadjuvant immunochemotherapy demonstrated superior efficacy and tolerable toxicity.Conclusion: According to our analysis, reliable efficacy, safety, and survival of neoadjuvant immunochemotherapy for operable NSCLC were demonstrated.Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022360893, identifier CRD42022360893.

16 July 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
QWQian Wang
Qian Wang
STShiyan Tan
Shiyan Tan
XFXi Fu
Xi Fu
JHJiawei He
Jiawei He
QMQiong Ma
Qiong Ma
YRYi-Feng Ren
Yi-Feng Ren
Background: Lung organoids have emerged as a promising tool for studying lung development, function, and disease pathology. The present study aimed to analyze the current status and development trends of lung organoid research over the past years, present visual representations, and provide references for future research directions using bibliometric analysis.Methods: Information on articles on lung organoids extracted from the Web of Science Core Collection, such as year of publication, journal, country, institution, author, and keywords, was analyzed. R, VOSviewer, and SCImago Graphica were used to visualize publication trends, co-authorship analysis, co-occurrence analysis, and hotspot evolution.Results: The number of global publications has increased from 1 in 2011 to 929 in 2024. The Nature produced the highest number of citations (2,675 citations). The United States (8,155 citations and 281 publications), University Medical Center Utrecht (2083 citations and 11 publications), and Clevers H (2,711 citations and 21 publications) were the most influential countries, institutions, and authors, respectively. Co-occurrence cluster analysis of the top 54 keywords formed four clusters: (1) idiopathic pulmonary fibrosis, (2) lung cancer, (3) cystic fibrosis, (4) COVID-19.Conclusion: Overall, research on lung organoids continues to increase. The United States of America and the Netherlands dominated global studies. The analysis of pulmonary fibrosis, lung cancer and COVID-19 occupied a prominent position of research in this area. The research hotspots for lung organoids are disease model and microphysiological systems. Standardization, accurate disease modeling, and ethics and safety remain pressing challenges that need to be addressed in this field.

14 October 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
HYHua You
Hua You
MFMingyu Fan
Mingyu Fan
LYLimei Yin
Limei Yin
FNFeifei Na
Feifei Na
LYLiting You
Liting You
This study delves into the landscape of RNA modification (RM)-related long non-coding RNAs (lncRNAs) within non-small cell lung cancer (NSCLC). We aim to uncover their significance in cancer biology and potential clinical implications. We utilized diverse datasets to identify 444 RM-related genes with 12 RMs. RM scores were computed, and associations with survival were analyzed. Weighted gene co-expression network analysis identified 730 RM-related lncRNAs. Univariate Cox regression identified 63 prognostically significant lncRNAs, leading to the classification of NSCLC samples into two clusters. Distinct differences in overall survival and disease-free interval were observed between the identified lncRNA clusters, showcasing their prognostic relevance. Molecular characterization uncovered mutation landscape variations, with cluster 2 displaying higher mutation rates in TP53 and TTN. Cluster-specific genomic alterations, immune cell infiltration, and immune checkpoint gene expression patterns were identified. Drug sensitivity analysis revealed distinct profiles, with cluster 1 showing potential resistance to a combined approach of certain chemotherapy and immunotherapy, while cluster 2 may be suitable for monotherapy with specific chemotherapeutic or targeted agents. In conclusion, this study stands as the first and most comprehensive exploration, elucidating the intricate connections between RM, lncRNAs, NSCLC, and tumor immunity. Its findings significantly enhance our comprehension of NSCLC heterogeneity, offering pivotal insights and paving the path toward personalized treatment strategies.

1 July 2025 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
YRYi-Feng Ren
Yi-Feng Ren
STShi-Yan Tan
Shi-Yan Tan
QWQian Wang
Qian Wang
JHJia-Wei He
Jia-Wei He
FYFeng-Ming You
Feng-Ming You
LYLiting You
Liting You
Background: The microbiota is intricately linked to lung cancer’s development, progression, diagnosis, and treatment, garnering significant academic interest. This study employs bibliometric methods to trace trends and advancements, emphasizing the extraction and analysis of clinical research data, and outlines current challenges and future research directions. Methods: We selected the literature in the Web of Science Core Collection database. To provide an overview, annual publications, countries/regions, and keywords were evaluated through a bibliometric analysis, and extracted and analyzed key clinical information. Results: A total of 579 publications were reviewed, with 177 clinical studies chosen for detailed analysis. These publications, spanning from 1997 to 2025, showed a consistent yearly increase in the number of articles, despite some fluctuations. Science and PLOS One were the most frequently cited journals in this area. Key contributors to this field include Yan Zhang, Jun Chen, Zoltan Lohinai, and Edit Dulka. China was the leading producer of publications, indicating its close monitoring of the field, though it did not emphasize international collaborations, resulting in less influential publications. Major topics in this field included lung cancer, gut microbiota, microbiome, immunotherapy, inflammation, and biomarkers. Future research will likely focus on biomarkers, machine learning, immunotherapy and mechanisms. Clinical studies have identified common microbiota, such as Prevotella, Bacteroidetes, Streptococcus, Veillonella, and Bacillus, as potential microbial biomarkers. Conclusion: This field has a bright research prospect, and there is a huge unmet clinical need. Future studies need to expand the sample size and further explore microbiota associated with the mechanisms, diagnosis, treatment and prognosis of lung cancer. Solving problems such as small sample size, heterogeneity of the population, sequencing bias, and precise diagnosis, conducting cross-regional and multicenter research, and identifying specific microbiota that have an important impact on cancer treatment are future challenges.